293
Participants
Start Date
April 30, 2012
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
Vildagliptin
Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
Placebo
Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Pasay
Novartis Investigative Site, Metro Manila
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Khon Kaen
Novartis Investigative Site, Beijing
Novartis Investigative Site, Shenyang
Novartis Investigative Site, Singapore
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Wuxi
Novartis Investigative Site, Jinan
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Nanchang
Novartis Investigative Site, Changsha
Novartis Investigative Site, Changsha
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Xi’an
Novartis Investigative Site, Singapore
Novartis Investigative Site, Beijing
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY